RT Book, Section
A1 Cohen, Philip R.
A1 Honigsmann, Herbert
A1 Kurzrock, Razelle
A2 Goldsmith, Lowell A.
A2 Katz, Stephen I.
A2 Gilchrest, Barbara A.
A2 Paller, Amy S.
A2 Leffell, David J.
A2 Wolff, Klaus
SR Print(0)
ID 56030398
T1 Chapter 32. Acute Febrile Neutrophilic Dermatosis (Sweet Syndrome)
T2 Fitzpatrick's Dermatology in General Medicine, 8e
YR 2012
FD 2012
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-166904-7
LK accessmedicine.mhmedical.com/content.aspx?aid=56030398
RD 2024/04/16
AB |PrintAcute  Febrile  Neutrophilic  Dermatosis  (Sweet  Syndrome)  at  a  GlanceAcute  febrile  neutrophilic  dermatosis  (Sweet  syndrome)  is  characterized  by  a  constellation  of  symptoms  and  findings:  the  acute  onset  of  fever,  neutrophilia,  erythematous,  and  tender  skin  lesions  that  typically  show  an  upper  dermal  infiltrate  of  mature  neutrophils,  and  the  prompt  improvement  of  both  symptoms  and  lesions  after  initiation  of  treatment  with  systemic  corticosteroids.Cardiovascular,  central  nervous  system,  gastrointestinal,  hepatic,  musculoskeletal,  ocular,  oral,  otic,  pulmonary,  renal,  and  splenic  organs  can  be  involved  by  the  extracutaneous  manifestations  of  Sweet  syndrome.Classical  Sweet  syndrome  may  be  associated  with  infection  of  the  upper  respiratory  tract  and/or  gastrointestinal  tract,  inflammatory  bowel  disease,  and  pregnancy.Malignancy-associated  Sweet  syndrome  occurs  in  individuals  with  previously  undiagnosed  or  relapsing  hematologic  malignancies  and  solid  tumors;  in  these  patients,  Sweet  syndrome  appears  as  a  cutaneous  paraneoplastic  syndrome.Drug-induced  Sweet  syndrome  describes  the  onset  of  dermatosis  in  patients  following  the  initiation  of  certain  medications—most  commonly  granulocyte-colony  stimulating  factor.Cytokines—directly  or  indirectly—may  have  an  important  etiologic  role  in  the  pathogenesis  of  this  dermatosis.The  first-line  oral  systemic  agents  for  treating  Sweet  syndrome  are  corticosteroids,  potassium  iodide,  and  colchicine.The  second-line  oral  systemic  agents  for  treating  Sweet  syndrome  are  indomethacin,  clofazimine,  cyclosporine,  and  dapsone.Topical  application  of  high-potency  corticosteroids  or  intralesional  corticosteroids  may  be  efficacious  for  treating  localized  Sweet  syndrome  lesions.